Jeanne M Perotin
University of Reims Champagne-Ardenne
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeanne M Perotin.
Respiratory Research | 2007
G. Deslee; S. Dury; Jeanne M Perotin; Denise Al Alam; F. Vitry; Rachel Boxio; Sophie C. Gangloff; Moncef Guenounou; F. Lebargy; Abderrazzaq Belaaouaj
BackgroundChronic obstructive pulmonary disease (COPD) is characterized by abnormal lung inflammation that exceeds the protective response. Various culture models using epithelial cell lines or primary cells have been used to investigate the contribution of bronchial epithelium in the exaggerated inflammation of COPD. However, these models do not mimic in vivo situations for several reasons (e.g, transformed epithelial cells, protease-mediated dissociation of primary cells, etc.). To circumvent these concerns, we developed a new epithelial cell culture model.MethodsUsing non transformed non dissociated bronchial epithelium obtained by bronchial brushings from COPD and non-COPD smokers, we developed a 3-dimensional culture model, bronchial epithelial spheroids (BES). BES were analyzed by videomicroscopy, light microscopy, immunofluorescence, and transmission electron microscopy. We also compared the inflammatory responses of COPD and non-COPD BES. In our study, we chose to stimulate BES with lipopolycaccharide (LPS) and measured the release of the pro-inflammatory mediators interleukin-8 (IL-8) and leukotriene B4 (LTB4) and the anti-inflammatory mediator prostaglandin E2 (PGE2).ResultsBES obtained from both COPD and non-COPD patients were characterized by a polarized bronchial epithelium with tight junctions and ciliary beating, composed of basal cells, secretory cells and ciliated cells. The ciliary beat frequency of ciliated cells was not significantly different between the two groups. Of interest, BES retained their characteristic features in culture up to 8 days. BES released the inflammatory mediators IL-8, PGE2 and LTB4 constitutively and following exposure to LPS. Interestingly, LPS induced a higher release of IL-8, but not PGE2 and LTB4 in COPD BES (p < 0.001) which correlated with lung function changes.ConclusionThis study provides for the first time a compelling evidence that the BES model provides an unaltered bronchial surface epithelium. More importantly, BES represent an attractive culture model to investigate the mechanisms of injuring agents that mediate epithelial cell inflammation and its contribution to COPD pathogenesis.
Revue Des Maladies Respiratoires | 2015
A. Zouak; É. Bongrain; C. Launois; J. Nardi; J. Vella-Boucaud; G. Deslee; F. Lebargy; Jeanne M Perotin
BACKGROUND Eosinophilic pleural effusions are defined by an eosinophil count ≥10% in pleural fluid and represent approximately 10% of exudative pleural effusions. OBSERVATION We report the first case of eosinophilic pleural effusion occurring due to lisinopril treatment. Improvement after drug discontinuation and recurrence after reintroduction indicated that lisinopril was responsible for the effusion. CONCLUSION The main causes of eosinophilic pleural effusions are infections including tuberculosis, and malignancies. Drug-induced eosinophilic pleural effusions have only rarely been described, mainly caused by cardiovascular or neuropsychiatric medicines.
Revue Des Maladies Respiratoires | 2015
A. Zouak; É. Bongrain; C. Launois; J. Nardi; J. Vella-Boucaud; G. Deslee; F. Lebargy; Jeanne M Perotin
BACKGROUND Eosinophilic pleural effusions are defined by an eosinophil count ≥10% in pleural fluid and represent approximately 10% of exudative pleural effusions. OBSERVATION We report the first case of eosinophilic pleural effusion occurring due to lisinopril treatment. Improvement after drug discontinuation and recurrence after reintroduction indicated that lisinopril was responsible for the effusion. CONCLUSION The main causes of eosinophilic pleural effusions are infections including tuberculosis, and malignancies. Drug-induced eosinophilic pleural effusions have only rarely been described, mainly caused by cardiovascular or neuropsychiatric medicines.
Revue Des Maladies Respiratoires | 2014
J. Vella-Boucaud; S. Chouabe; F. Bourin; J. Nardi; Jeanne M Perotin; F. Lebargy; G. Deslee
Revue Des Maladies Respiratoires | 2011
Jeanne M Perotin; G. Deslee; D. Perdu; V. Cahn; Pierre Validire; S. Rubin; Pierre Magdeleinat; Olivier Toubas; F. Lebargy
Revue Des Maladies Respiratoires | 2016
Y. Ammar; J. Vella-Boucaud; Claire Launois; H. Vallerand; Sandra Dury; F. Lebargy; Gaëtan Deslée; Jeanne M Perotin
Revue Des Maladies Respiratoires | 2015
J. Vella-Boucaud; D. Papathanassiou; O. Bouche; A. Prevost; T. Lestra; J. Nardi; Jeanne M Perotin; C. Launois; M. Brasseur; F. Lebargy; G. Deslee
Revue Des Maladies Respiratoires | 2014
Y. Ammar; J.L. Lampaert; J. Nardi; Jeanne M Perotin; D.P.D. Perdu; F. Lebargy; G. Deslee
Revue Des Maladies Respiratoires | 2011
Jeanne M Perotin; G. Deslee; D. Perdu; Virginie Cahn; Pierre Validire; Sarah S. Rubin; Pierre Magdeleinat; Olivier Toubas; F. Lebargy
Revue de Médecine Interne | 2010
John M. Salmon; Jeanne M Perotin; J. Leone; F. Lebargy; J.-L. Pennaforte